Efficacy and Safety Assessments of a Peritoneal Dialysis Solution Containing Glucose, Xylitol, and L-Carnitine in CAPD
Efficacy and Safety Assessments of a Peritoneal Dialysis Solution Containing Glucose, Xylitol and L-Carnitine Compared to Standard PD Solutions in Continuous Ambulatory Peritoneal Dialysis (CAPD)
Sponsor: Iperboreal Pharma Srl
Terminated
prematurely interrupted due to significant difficulties in the completion of the sample size defined by the study protocol
Other End Stage Renal Disease trials with similar outcome
Listed as NCT04001036, this PHASE2 trial focuses on End Stage Renal Disease and remains terminated or withdrawn. Sponsored by Iperboreal Pharma Srl, it has been updated 9 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Apr 2023 — Jul 2024 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Sep 2022 — Apr 2023 [monthly]
Recruiting PHASE2
-
Sep 2021 — Sep 2022 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Mar 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE2
-
Feb 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2019 — Feb 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Iperboreal Pharma Srl
For direct contact, visit the study record on ClinicalTrials.gov .